The common view has long held that only 20–30% of patients with the anti-GBM disease have the detectable antineutrophil cytoplasmic antibody, especially against myeloperoxidase (MPO), namely, the “double positive” (Hellmark et al., 1997). The gene discussed is MPO; the disease is glioblastoma.